By Paul Candon Credit: Journal of Studies on Alcohol and Drugs By Paul Candon PISCATAWAY, NJ — From 2019 to 2020, more than 11,000 people who...
ArtsBerry invited the Senior Designer behind Lark Suite to share her creative design ideas and process of the suite of office collaboration tools focusing...
Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) is pleased to announce it has entered into a Letter of Intent with Medelys Laboratories...
Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) announced today its intention to commence a normal course issuer bid, under which the Company...
VANCOUVER, British Columbia, Aug. 18, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0), an international sexual health and wellness company,...
In this edition of Weekly Extractions, host Adam Tubero provides an update on a story we’ve been following closely over the past several weeks. For starters,...
David Yaden, whose new book continues the legacy of William James’s work on spiritual experiences, talks about James’s mystical encounter with nitrous...
The article How Interdisciplinary Research Could Reveal Psychedelics’ Blind Spots was originally published on Microdose. Most psychedelic research is...
CaaMTech scientists, in collaboration with the Manke Lab at UMass Dartmouth, recently reported their synthesis and structural characterization of two...
Credit: Photo illustration/UC Psychedelics such as magic mushrooms offer promise for addressing addiction, post-traumatic stress and other difficult-to-treat...
The article APA Issues Position Statement on Psychedelics was originally published on Microdose. This past July, America’s oldest medical association,...
As the public perception of psychedelics begins to shift, so too are the regulations that govern them. Back in 2020, Oregon became the first state in...
Researchers are comparing near-death experiences (NDE) to psychedelics-imagined “death” experiences to learn more about both. The post Psychedelics...
Universal Ibogaine Inc.(TSXV:IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it’s...
BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine The post NICE says yes to BeiGene’s...